A pilot study of stanozolol for advanced breast carcinoma

Abstract

Eighteen patients with advanced metastatic carcinoma of the breast who had been previously treated with other hormone therapy were treated with stanozolol in a pilot study to assess its efficacy and toxicity. In a heavily pretreated population of patients with advanced breast cancer, three patients (16.6%) had partial responses (PR) and five patients (27.7%) had stable disease (SD). Toxicity was far less than that expected with androgen therapy. Stanozolol should be investigated in large groups of patients to establish its role more fully in the management of metastatic breast carcinoma.

Acceleration of neutrophil precursors’ maturation and immunostimulation of CD3+, CD4+ lymphocytes by stanozolol in mice

“…In fact, AAS were originally developed for therapeutic treatment (usually in small doses) of aplastic anemia, endometriosis, male hypogonadism, inoperable breast cancer, hereditary angioedema and osteoporosis [1][2][3][4][5][6][7]. In addition to these legitimate therapeutic applications, AAS compounds are being abused by many recreational and professional athletes to improve physique, athletic performance, to enhance muscle mass, strength and endurance [8][9][10].…”